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Purpose of the study
HIV infection itself and antiretroviral treatment, espe-
cially nucleoside analogue reverse transcriptase inhibitors
(NRTIs), cause mitochondrial impairment in HIV-
infected patients, due to the inhibition of ã-polymerase,
the only enzyme responsible for mitochondrial DNA
(mtDNA) replication. We investigated whether there are
changes in mtDNA content after 1 year of treatment inter-
ruption in children.
Methods
Mitochondrial DNA (mtDNA) was assessed by Real-Time
Polymerase Chain Reaction (RT-PCR) in peripheral blood
mononuclear cells (PBMCs) of 13 perinatally-HIV-
infected pediatric patients, who underwent planned treat-
ment interruption (PTI). MtDNA was measured at the
time of PTI and 12 months later. A sequence of a highly
conserved mtND2 gene and a fragment of the nuclear-
coded housekeeping 18SrRNA gene were amplified sepa-
rately. Changes in mtDNA amount were expressed as the
ratio of ND2 mtDNA with respect to 18SrRNAnDNA.
Summary of results
MtDNA content significantly increased from 0.89 ± 0.173
to 1.48 ± 0.3429 (66%, p < 0.05) after 12-month treat-
ment interruption.
Conclusion
MtDNA content restoration was found in a group of peri-
natally HIV-infected pediatric patients after 12 months of
HAART interruption. Our results suggest that mitochon-
drial damage is rather due to the use of nucleoside ana-
logues than to HIV infection itself. In this setting, it is
important to investigate new therapeutic treatment-spar-
ing strategies in HIV-infected pediatric patients.
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